These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 33298727)

  • 1. Immunotherapy for Lung Cancer-Improving Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer With Immunotherapy.
    Sun L; Aggarwal C
    Cancer J; 2020; 26(6):548-554. PubMed ID: 33298727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locally Advanced, Unresectable Non-Small Cell Lung Cancer.
    Puri S; Saltos A; Perez B; Le X; Gray JE
    Curr Oncol Rep; 2020 Mar; 22(4):31. PubMed ID: 32140986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
    Rajappa S; Sharma S; Prasad K
    Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer.
    Loh J; Low JL; Sachdeva M; Low PQ; Wong RSJ; Huang Y; Chia PL; Soo RA
    Expert Rev Anticancer Ther; 2023; 23(9):913-926. PubMed ID: 37551698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role of immunotherapy in locally advanced non-small cell lung cancer.
    Mulherkar R; Grewal AS; Berman AT
    Clin Adv Hematol Oncol; 2020 Apr; 18(4):212-217. PubMed ID: 32628649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report.
    Yang RX; Hei Y; Zhu WT; Wang QR; Zhang HM; Chen Y
    Curr Oncol; 2022 Aug; 29(9):6203-6210. PubMed ID: 36135056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoradiotherapy of locally advanced nonsmall cell lung cancer: state of the art and perspectives.
    Antoni D; Mornex F
    Curr Opin Oncol; 2016 Mar; 28(2):104-9. PubMed ID: 26848885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
    Jain AK; Hughes RS; Sandler AB; Dowlati A; Schwartzberg LS; Dobbs T; Schlabach L; Wu J; Muldowney NJ; Choy H
    J Thorac Oncol; 2009 Jun; 4(6):722-7. PubMed ID: 19404213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination of chemotherapy and radiotherapy for locally advanced non-small cell lung cancer].
    Fournel P
    Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S94-100. PubMed ID: 18235400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer.
    Vokes EE; Crawford J; Bogart J; Socinski MA; Clamon G; Green MR
    Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5045s-5050s. PubMed ID: 16000612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoradiotherapy in locally advanced, unresectable non-small cell lung cancer.
    Mitchell LR; Albert JM; Lu B
    Rev Recent Clin Trials; 2009 May; 4(2):110-21. PubMed ID: 19463107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
    Fukui T; Hosotani S; Soda I; Ozawa T; Kusuhara S; Kakegawa MI; Kasajima M; Hiyoshi Y; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Ishiyama H; Naoki K
    Thorac Cancer; 2020 Apr; 11(4):1005-1014. PubMed ID: 32057187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in systemic therapy for non-small cell lung cancer.
    Miller M; Hanna N
    BMJ; 2021 Nov; 375():n2363. PubMed ID: 34753715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung Cancer.
    Brade A; Jao K; Yu S; Cheema P; Doucette S; Christofides A; Schellenberg D
    Curr Oncol; 2021 Apr; 28(3):1618-1629. PubMed ID: 33923355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
    Bi N; Liang J; Zhou Z; Chen D; Fu Z; Yang X; Feng Q; Hui Z; Xiao Z; Lv J; Wang X; Zhang T; Wang X; Deng L; Wang W; Wang J; Liu L; Hu C; Wang L
    JAMA Netw Open; 2019 Dec; 2(12):e1918070. PubMed ID: 31851351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation.
    Penland SK; Socinski MA
    Semin Radiat Oncol; 2004 Oct; 14(4):326-34. PubMed ID: 15558508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer.
    Ready NE; Vokes EE
    Lung Cancer; 2003 Dec; 42 Suppl 1():S65-9. PubMed ID: 14611917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is concurrent chemoradiation the standard of care for locally advanced non-small cell lung cancer? A review of guidelines and evidence.
    O'Rourke N; Macbeth F
    Clin Oncol (R Coll Radiol); 2010 Jun; 22(5):347-55. PubMed ID: 20427167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.